Logical Assessment
Long/short equity, biotech, small-cap, micro-cap

While Amarin Continues To Go Rancid, Neptune Will Soar

What's Next For Amarin Investors?

It's been an emotional and financial rollercoaster for Amarin (NASDAQ:AMRN), with the hype surrounding Vascepa leaving investors deep underwater, gasping for air.

(click to enlarge)

Since attaining FDA approval for its lead product on July 26 last year, shares began and continued to tumble, with the negative FDA advisory committee panel meeting dealing a near coup de grace to the proverbial Pequod. Consequently, Amarin's high-profile failure has served to largely sour investors on companies with fish-oil or similar products. Enter Neptune Technologies & Bioresources (NASDAQ:NEPT), a similar company that is significantly de-risked and poised for double to triple digit returns over the next year.

Unless otherwise noted, financial statistics and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details